[go: up one dir, main page]

WO2020177714A1 - 一种羊毛甾醇前药化合物的组合物及其制备方法和应用 - Google Patents

一种羊毛甾醇前药化合物的组合物及其制备方法和应用 Download PDF

Info

Publication number
WO2020177714A1
WO2020177714A1 PCT/CN2020/077765 CN2020077765W WO2020177714A1 WO 2020177714 A1 WO2020177714 A1 WO 2020177714A1 CN 2020077765 W CN2020077765 W CN 2020077765W WO 2020177714 A1 WO2020177714 A1 WO 2020177714A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
composition according
tween
peg400
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/077765
Other languages
English (en)
French (fr)
Inventor
刘奕志
王延东
李小林
罗志
贺海鹰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongshan Ophthalmic Center
Original Assignee
Zhongshan Ophthalmic Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongshan Ophthalmic Center filed Critical Zhongshan Ophthalmic Center
Priority to US17/435,668 priority Critical patent/US12329763B2/en
Publication of WO2020177714A1 publication Critical patent/WO2020177714A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Definitions

  • the present invention relates to a composition containing a compound represented by formula (I) and a preparation method thereof, and its application in preparing medicines for treating ophthalmic diseases.
  • Cataract is a disease of the eye that occurs on the lens inside the eyeball.
  • the opacity of the lens is collectively called cataract.
  • Aging, heredity, metabolic abnormalities, trauma, radiation, poisoning, and local malnutrition can all cause damage to the lens capsule, increase its permeability, lose its barrier function, or cause disorders of lens metabolism, denature lens proteins, and form turbidity.
  • the lens of the eyeball changes from transparent to opaque, which affects the eyes to receive sunlight, it will affect the vision of the eyes.
  • the opacity of the eyeballs is light, the impact on vision is lighter.
  • the degree of opacity gradually deepens the vision will increase, and severe cases can lead to blindness.
  • Cataract is one of the most common blinding eye diseases, and it is the main cause of blindness. Since the mechanism of cataract formation is still unclear, no breakthrough has been made in drug treatment so far. Therefore, the only definite effective treatment at present is surgery.
  • clinical treatment drugs for cataracts include: 1Aldose reductase inhibitors, such as cataline (catalin, carlinyou, dianetopin), facolin, bental lysine, etc.; 2anti- Oxidative damage drugs, such as glutathione, taurine, aspirin, etc.; 3Nutrition metabolism drugs, such as vitamins, carotenoids, etc.; 4 Chinese medicine compounds include Dendrobium Yeguang Pill, Qiju Dihuang Pill, Shijue Ming Powder, etc.
  • these drugs for the treatment of cataracts have been confirmed by long-term clinical trials, which can only delay the deterioration of the cataract, but cannot reverse the condition, so as to treat the cataract.
  • Lanosterol is an amphiphilic molecule enriched in the lens. It is synthesized by a key cyclization reaction of lanosterol synthase (LSS) in the cholesterol synthesis pathway. It can reduce the abnormal aggregation of lens protein and make it renew Arrange regularly to restore crystal transparency. Studies have shown that lanosterol synthase can be detected in the lens. In addition, in the Shumiya cataract rat study, a specific combination of homozygous mutations of lanosterol synthase and farnesyl diphosphate transferase 1 (FDFT1) can reduce the level of cholesterol in the lens and cause cataracts.
  • LDS lanosterol synthase
  • FDFT1 farnesyl diphosphate transferase 1
  • Kalinyou eye drops produced by the Japan Santen Pharmaceutical Zhushi Company, are used to treat early-stage senile cataracts.
  • the structural formula of its active ingredients is as follows:
  • the present invention provides a composition comprising a compound of formula (I) and auxiliary materials,
  • the content of the compound represented by the above formula (I) is 0.1-0.3%.
  • auxiliary materials are selected from the group consisting of solubilizers, pH regulators, osmotic pressure regulators, surfactants, thickeners, moisturizers, binders, suspending agents, dispersants, lubricants and water One or several combinations.
  • the above-mentioned solubilizing agent is selected from HCl, polyethylene glycol 200 (PEG200), polyethylene glycol 400 (PEG400), glycerin, beloxamer 407, polyethylene oxide (PEO), sulfobutyl -B-cyclodextrin (SBE- ⁇ -CD), hydroxypropyl- ⁇ -cyclodextrin (HP- ⁇ -CD), Beloxamer 188, polyvinylpyrrolidone (PVP) and one of Tween 80 Kind or a combination of several.
  • the above-mentioned pH adjusting agent is selected from one or a combination of HCl, Tris-HCl, citric acid buffer and NaOH.
  • the above-mentioned osmotic pressure regulator is selected from the group consisting of phosphate buffered saline (PBS), sodium hyaluronate, dipotassium ethylenediaminetetraacetate (EDTA-K 2 ), disodium ethylenediaminetetraacetate (EDTA -Na 2 ) and a combination of one or more of amino acid pH adjusters.
  • PBS phosphate buffered saline
  • EDTA-K 2 dipotassium ethylenediaminetetraacetate
  • EDTA -Na 2 disodium ethylenediaminetetraacetate
  • the above-mentioned surfactant is selected from one or a combination of Tween 80, Tween 20 and hydrogenated castor oil.
  • the above-mentioned thickener is selected from PEG200, glycerin, PEG400, beloxamer 188, beloxamer 407, PEO, polyoxyethylene castor oil, sodium hyaluronate, sodium carboxymethyl cellulose , Methyl cellulose (MC), carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC), cellulose acetate (CAP) and hydroxypropyl methyl cellulose (HPMC E5) Or a combination of several.
  • the above-mentioned moisturizer is selected from one or a combination of glycerin, PEG200 and PEG400.
  • the above-mentioned binder is selected from one or a combination of beloxamer 407, PEO, PVP, sodium carboxymethyl cellulose, MC, CMC, HEC, CAP, and HPMC E5.
  • the above-mentioned suspending agent is selected from one or a combination of several of sodium carboxymethyl cellulose, MC, CMC, HEC, CAP and HPMC E5.
  • the above-mentioned dispersing agent is selected from one or a combination of glycerin, PEG200 and PEG400.
  • the aforementioned lubricant is selected from one or a combination of glycerin, PEG200 and PEG400.
  • the present invention also provides a composition which is:
  • the above-mentioned composition is an ophthalmic preparation for treating cataract.
  • the above-mentioned ophthalmic preparation is eye drops.
  • the specification of the above-mentioned eye drops is 10 mL.
  • composition of the present invention can alleviate cataract symptoms, improve lens transparency and lens GSH-PX activity.
  • the intermediate compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those skilled in the art.
  • Well-known equivalent alternatives, preferred implementations include but are not limited to the embodiments of the present invention.
  • excipient generally refers to the carrier, diluent and/or medium required to formulate an effective pharmaceutical composition.
  • the solvent used in the present invention is commercially available.
  • PEG400 polyethylene glycol 400
  • PVP polyvinylpyrrolidone
  • HP- ⁇ -CD hydroxypropyl ⁇ cyclodextrin.
  • Figure 1 The effect of slit lamp observation prescription 9 on sodium selenite-induced neonatal New Zealand rabbit cataract model.
  • NC Normal control group (Normal control group);
  • MC Model control group (Model control group);
  • PC Positive control group (Positive control group);
  • LT Lanosterol eye drops treatment group (Lanosterol eye drops treatment group).
  • Figure 2 Comparison of in vitro lens transparency test results of each group in a newborn New Zealand rabbit cataract model induced by sodium selenite 42 days after administration.
  • NC Normal control group (Normal control group);
  • MC Model control group (Model control group);
  • PC Positive control group (Positive control group);
  • LT Lanosterol eye drops treatment group (Lanosterol eye drops treatment group).
  • the grid is 2.12 ⁇ 2.12mm
  • Figure 3 Comparison of the detection results of the lens glutathione peroxidase (GSH-PX) activity of each group in the newborn New Zealand rabbit cataract model induced by sodium selenite 42 days after administration.
  • NC Normal control group (Normal control group); MC: Model control group (Model control group); PC: Positive control group (Positive control group); LT: Lanosterol eye drops treatment group (Lanosterol eye drops treatment group).
  • V.S PC ++ means p ⁇ 0.01, + means p ⁇ 0.05.
  • Figure 4 Slit lamp observation of the effect of prescription 9 on ultraviolet-induced New Zealand rabbit cataract model.
  • NC Normal control group (Normal control group);
  • MC Model control group (Model control group);
  • PC Positive control group (Positive control group);
  • LT Lanosterol eye drops treatment group (Lanosterol eye drops treatment group).
  • Figure 5 Comparison of the results of in vitro lens transparency detection of each group in the ultraviolet-induced New Zealand rabbit cataract model 42 days after administration.
  • NC Normal control group (Normal control group);
  • MC Model control group (Model control group);
  • PC Positive control group (Positive control group);
  • LT Lanosterol eye drops treatment group (Lanosterol eye drops treatment group).
  • the grid is 2.12 ⁇ 2.12mm.
  • Figure 6 Comparison of the detection results of the lens glutathione peroxidase (GSH-PX) activity of each group in the ultraviolet-induced New Zealand rabbit cataract model 42 days after the administration.
  • NC Normal control group (Normal control group); MC: Model control group (Model control group); PC: Positive control group (Positive control group); LT: Lanosterol eye drops treatment group (Lanosterol eye drops treatment group).
  • V.S PC ++ means p ⁇ 0.01, + means p ⁇ 0.05.
  • New Zealand rabbits P7 days old, ordinary grade, each litter of 5 young rabbits with a mother rabbit suckling.
  • the experimental rabbits were randomly divided into 5 groups, each with 5 rabbits.
  • NC Normal control group
  • Model control group On day P10, young rabbits were injected with sodium selenite solution (in physiological saline) 20 ⁇ mol/kg body weight subcutaneously in the neck, and after P15 days, they were given blank drops without drugs for 42 consecutive days Drop the eye drops to the right eye 3 times a day.
  • PC Positive control group
  • Lanosterol eye drops treatment group On day P10, young rabbits were injected with sodium selenite solution (in saline) 20 ⁇ mol/kg body weight into the neck subcutaneously, and used for 42 consecutive days after P15 Lanosterol eye drops were applied to the right eye 3 times a day.
  • GSH-PX activity detection kit Najing Jiancheng Institute of Bioengineering
  • the experimental data was analyzed by One-Way ANOVA with SPSS statistical software, and the LSD method was used for comparison between groups. The statistical difference level was p ⁇ 0.05.
  • Figure 1 shows that sodium selenite can induce cataracts in the lens of newborn New Zealand rabbits.
  • Figure 1-E, 1-F Kalinyou eye drops
  • Figure 1-G, 1-H lanosterol eye drops
  • Figure 2 compares the lens transparency of each group in the newborn New Zealand rabbit cataract model induced by sodium selenite 42 days after the administration.
  • the left eye of each photo is the lens of the left eye (the left eye is not administered, as a self-control), and the lens on the right is the lens of the right eye (the right eye is administered according to different groups). 42 days after prescription 9 was administered, the transparency of the right eye lens was significantly higher than that of its own left eye, and it was also significantly higher than that of the MC group lens, but still lower than that of the NC group.
  • the lens transparency of the right eye in the LT group did not change significantly after administration.
  • prescription 9 can alleviate the symptoms of cataract in newborn New Zealand rabbits induced by sodium selenite, improve lens transparency and lens GSH-PX activity.
  • the experimental animals were randomly divided into 5 groups with 5 animals in each group.
  • Normal control group Normal control group, NC: Normally raised, no medication.
  • Model control group (MC) 313nm ultraviolet rays were irradiated for 24 hours to build the model, and then the right eye was dripped with drug-free blank eye drops for 42 consecutive days, 3 times a day.
  • PC Positive control group
  • Lanosterol eye drops treatment group (LT) 313nm ultraviolet rays were irradiated for 24 hours to build the model, and then the right eye was dripped with lanosterol eye drops for 42 consecutive days, 3 times a day.
  • GSH-PX activity detection kit Najing Jiancheng Institute of Bioengineering
  • the experimental data was analyzed by One-Way ANOVA with SPSS statistical software, and the LSD method was used for comparison between groups. The statistical difference level was p ⁇ 0.05.
  • Figure 5 compares the lens transparency of each group in the ultraviolet-induced New Zealand rabbit cataract model 42 days after the administration.
  • the left eye of each photo is the lens of the left eye (the left eye is not administered, as a self-control), and the lens on the right is the lens of the right eye (the right eye is administered according to different groups). 42 days after prescription 9 was administered, the transparency of the right eye lens was significantly higher than that of its own left eye, and it was also significantly higher than that of the MC group lens, but still lower than that of the NC group.
  • the lens transparency of the right eye in the LT group did not change significantly after administration.
  • GSH-PX activity detection The GSH-PX activity detection results of the lens of each group 42 days after the administration showed (see Figure 6), after ultraviolet radiation, the GSH-PX activity of the rabbit eye lens was significantly reduced, which was statistically compared with the NC group Academic difference (p ⁇ 0.01 or p ⁇ 0.05).
  • Prescription 9 and the positive control drug Kalinyou eye drops can increase the lens GSH-PX activity, which is statistically different compared with the MC group (p ⁇ 0.01), and the improvement effect of prescription 9 is more obvious than that of Kalinyou (p ⁇ 0.05).
  • the effect of lanosterol eye drops on the activity of lens GSH-PX was significantly lower than that of prescription 9 and kalinyou, and there was no statistical difference compared with the MC group (p>0.05).
  • prescription 9 can reduce ultraviolet-induced cataract symptoms in New Zealand rabbits, improve lens transparency and lens GSH-PX activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

公开了一种包含式(I)所示化合物的组合物及其制备方法，及其在制备治疗眼科疾病的药物上的应用。

Description

一种羊毛甾醇前药化合物的组合物及其制备方法和应用
本申请主张如下优先权：
CN201910161146.7，申请日2019.03.04。
技术领域
本发明涉及一种包含式(Ⅰ)所示化合物的组合物及其制备方法，及其在制备治疗眼科疾病的药物上的应用。
背景技术
白内障属于眼睛的疾病，发生在眼球内的晶状体上，晶状体的浑浊统称为白内障。老化、遗传、代谢异常、外伤、辐射、中毒和局部营养不良等都可引起晶状体囊膜损伤，使其渗透性增加，丧失屏障作用，或导致晶状体代谢紊乱，使晶状体蛋白发生变性，形成混浊。如果眼球的晶状体从透明变成不透明、影响到眼睛接收阳光，那么就会影响眼睛的视力情况。在眼球浑浊较轻时对视力的影响较轻，随着浑浊的程度逐渐加深，视力也会随之加大，严重者会导致失明。白内障是最常见的致盲眼病之一，它是导致失明的主要因素。由于白内障形成的机制尚不明确，药物治疗至今未取得突破性进展。因此，目前唯一确定有效的治疗方法就是手术治疗。
尽管白内障手术方式的不断进步为白内障的治疗提供了巨大的帮助，但手术治疗的治愈率仍然远远低于发生率，存在发生严重并发症的可能；另一方面，白内障的手术治疗成本十分高昂，即使是发达国家，白内障也给医疗保险体系带来了巨大的负担。因此药物的防治起到举足轻重的作用。目前，临床上针对白内障的治疗药物包括：①醛糖还原酶抑制剂，如卡他林(卡他灵、卡林优、白内停)、法可林、苄达赖氨酸等；②抗氧化损伤药物，如谷胱甘肽、牛磺酸、阿司匹林等；③营养代谢类药物，如维生素类、类胡萝卜素等；④中药复方包括石斛夜光丸、杞菊地黄丸、石决明散等。而这些治疗白内障的药物经长期临床试验证实，只能延缓白内障的病情恶化，不能使病情逆转，从而治疗白内障。同时，随着我国开始步入老龄化社会，白内障患者日益增多，对于白内障药物的需求将更为迫切。因此，临床上非常需要安全、疗效好、眼内穿透力强、性质稳定的新品种眼科外用抗白内障药物。
羊毛甾醇是富集于晶状体内的两亲性分子，它是由羊毛甾醇合酶(LSS)在胆固醇合成途径中的一个关键的环化反应来合成，能够降低晶状体蛋白的异常聚集，使其重新规则排列从而恢复晶体透明。已有研究表明，在晶状体中可以检测到羊毛甾醇合酶。此外，在Shumiya白内障大鼠研究中，毛甾醇合酶和法尼基二磷酸法尼基转移酶1(FDFT1)的纯合突变特定组合可以减轻晶状体中胆固醇的水平，并导致白内障。同时我们最近的研究发现，羊毛甾醇在体外和细胞水平可以显著降低预形成的晶状体蛋白质聚集体。在在体水平也证实，羊毛甾醇可以使白内障的病情逆转，晶状体变的澄清透明，此结果已近期发表在Nature杂志，引起全世界广泛注意，是预防和治疗白内障的新分子。
Figure PCTCN2020077765-appb-000001
卡林优滴眼液，是由日本参天制药珠式会社生产的，用于治疗初期老年性白内障的药物，其有效成分的结构式如下：
Figure PCTCN2020077765-appb-000002
发明内容
本发明提供了一种组合物，包含式(Ⅰ)化合物和辅料，
Figure PCTCN2020077765-appb-000003
本发明的一些方案中，上述式(Ⅰ)所示化合物的含量为0.1～0.3％。
本发明的一些方案中，上述辅料选自增溶剂、PH调节剂、渗透压调节剂、表面活性剂、增稠剂、保湿剂、粘合剂、助悬剂、分散剂、润滑剂和水中的一种或几种的组合。
本发明的一些方案中，上述增溶剂选自HCl、聚乙二醇200(PEG200)、聚乙二醇400(PEG400)、甘油、伯洛沙姆407、聚氧化乙烯(PEO)、磺丁基-B-环糊精(SBE-β-CD)、羟丙基-β-环糊精(HP-β-CD)、伯洛沙姆188、聚乙烯吡咯烷酮(PVP)和吐温80中的一种或几种的组合。
本发明的一些方案中，上述PH调节剂选自HCl、Tris-HCl、柠檬酸缓冲液和NaOH中的一种或几种的组合。
本发明的一些方案中，上述渗透压调节剂选自磷酸盐缓冲液(PBS)、透明质酸钠、乙二胺四乙酸二钾(EDTA-K 2)、乙二胺四乙酸二钠(EDTA-Na 2)和氨基酸类pH调节剂中的一种或几种的组合。
本发明的一些方案中，上述表面活性剂选自吐温80、吐温20和氢化蓖麻油中的一种或几种的组合。
本发明的一些方案中，上述增稠剂选自PEG200、甘油、PEG400、伯洛沙姆188、伯洛沙姆407、PEO、聚氧乙烯蓖麻油、透明质酸钠、羧甲基纤维素钠、甲基纤维素(MC)、羧甲基纤维素(CMC)、羟乙基纤维素(HEC)、纤维醋法酯(CAP)和羟丙基甲基纤维素(HPMC E5)中的一种或几种的组合。
本发明的一些方案中，上述保湿剂选自甘油、PEG200和PEG400中的一种或几种的组合。
本发明的一些方案中，上述粘合剂选自伯洛沙姆407、PEO、PVP、羧甲基纤维素钠、MC、CMC、HEC、CAP和HPMC E5中的一种或几种的组合。
本发明的一些方案中，上述助悬剂选自羧甲基纤维素钠、MC、CMC、HEC、CAP和HPMC E5中的一种或几种的组合。
本发明的一些方案中，上述分散剂选自甘油、PEG200和PEG400中的一种或几种的组合。
本发明的一些方案中，上述润滑剂选自甘油、PEG200和PEG400中的一种或几种的组合。
本发明还提供了一种组合物为：
(1)式(Ⅰ)化合物30.38mg，0.05mol/L HCl溶液1.971mL，EDTA-Na 2 1mg，10％吐温80水溶液0.808mL，5N NaOH水溶液：11.8μL，水6.421mL；
(2)式(Ⅰ)化合物30.38mg，0.500mL PEG400，EDTA-Na 2 1mg，PBS 0.1mL，2.009g伯洛沙姆188，水7.459mL；
(3)式(Ⅰ)化合物30.38mg，0.05mol/L HCl水溶液0.500mL，10％吐温80水溶液0.800mL，10％聚氧乙烯蓖麻油溶液0.800mL，甘油0.080mL，0.1％透明质酸钠溶液7.818mL；
(4)式(Ⅰ)化合物30.38mg，0.500mL PEG400，1.900g伯洛沙姆188，0.1％透明质酸钠溶液：7.570mL；
(5)式(Ⅰ)化合物30.38mg，0.400mL PEG400，0.040mL吐温80，1mg EDTA-K 2，0.1％透明质酸钠溶液9.529mL；
(6)式(Ⅰ)化合物10mg，HP-β-CD 500mg，0.100mL吐温80，50mg PVP，水9.340mL；
(7)式(Ⅰ)化合物10mg，羧甲基纤维素钠50mg，50mg吐温80，水9.99mL；
(8)式(Ⅰ)化合物10mg，0.45g PEG400，0.025g吐温80，PVP 0.025g，HP-β-CD 0.475g，水8.515mL；
或(9)式(Ⅰ)化合物30.38mg，HPMC E5 0.12g，泊洛沙姆P407 2.05g，泊洛沙姆P188 0.16g，水7.67mL。
本发明的一些方案中，上述组合物是用于治疗白内障的眼用制剂。
本发明的一些方案中，上述眼用制剂是滴眼液。
本发明的一些方案中，上述滴眼液的规格为10mL。
技术效果
本发明的组合物可减轻白内障症状、提高晶状体透明度以及晶状体GSH-PX活性。
定义和说明
除非另有说明，本文所用的下列术语和短语旨在含有下列含义。一个特定的短语或术语在没有特别定义的情况下不应该被认为是不确定的或不清楚的，而应该按照普通的含义去理解。当本文出现商品名时，旨在指代其对应的商品或其活性成分。
本发明的中间体化合物可以通过本领域技术人员所熟知的多种合成方法来制备，包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式，优选的实施方式包括但不限于本发明的实施例。
术语“赋形剂”通常是指配制有效的药物组合物所需要载体、稀释剂和/或介质。
本发明具体实施方式的化学反应是在合适的溶剂中完成的，所述的溶剂须适合于本发明的化学变化及其所需的试剂和物料。为了获得本发明的化合物，有时需要本领域技术人员在已有实施方式的基础上对合成步骤或者反应流程进行修改或选择。
下面会通过实施例具体描述本发明，这些实施例并不意味着对本发明的任何限制。
本发明所使用的所有溶剂是市售的，无需进一步纯化即可使用。
本发明所使用的溶剂可经市售获得。
本发明采用下述缩略词：PEG400：聚乙二醇400；PVP：聚乙烯吡咯烷酮；HP-β-CD：羟丙基β环糊精。
附图说明
图1：裂隙灯观察处方9对亚硒酸钠诱导的新生新西兰兔白内障模型的作用。NC：正常对照组(Normal control group)；MC：模型对照组(Model control group)；PC：阳性对照组(Positive control group)；LT：羊毛甾醇滴眼液处理组(Lanosterol eye drops treatment group)。
图2：亚硒酸钠诱导的新生新西兰兔白内障模型在给药42天后各组体外晶状体透明度检测结果比较。NC：正常对照组(Normal control group)；MC：模型对照组(Model control group)；PC：阳性对照组(Positive control group)；LT：羊毛甾醇滴眼液处理组(Lanosterol eye drops treatment group)。网格为2.12×2.12mm
图3：亚硒酸钠诱导的新生新西兰兔白内障模型在给药42天后各组的晶状体谷胱甘肽过氧化物酶(Glutathione peroxidase,GSH-PX)活性检测结果比较。NC：正常对照组(Normal control group)；MC：模型对照组(Model control group)；PC：阳性对照组(Positive control group)；LT：羊毛甾醇滴眼液处理组(Lanosterol eye drops treatment group)。V.S NC：﹡﹡表示p﹤0.01,﹡表示p﹤0.05；V.S MC：##表示p﹤0.01,#表示p﹤0.05；V.S PC：++表示p﹤0.01,+表示p﹤0.05。
图4：裂隙灯观察处方9对紫外线诱导的新西兰兔白内障模型的作用。NC：正常对照组(Normal control  group)；MC：模型对照组(Model control group)；PC：阳性对照组(Positive control group)；LT：羊毛甾醇滴眼液处理组(Lanosterol eye drops treatment group)。
图5：紫外线诱导的新西兰兔白内障模型在给药42天后各组体外晶状体透明度检测结果比较。NC：正常对照组(Normal control group)；MC：模型对照组(Model control group)；PC：阳性对照组(Positive control group)；LT：羊毛甾醇滴眼液处理组(Lanosterol eye drops treatment group)。网格为2.12×2.12mm。
图6：紫外线诱导的新西兰兔白内障模型在给药42天后各组的晶状体谷胱甘肽过氧化物酶(Glutathione peroxidase,GSH-PX)活性检测结果比较。NC：正常对照组(Normal control group)；MC：模型对照组(Model control group)；PC：阳性对照组(Positive control group)；LT：羊毛甾醇滴眼液处理组(Lanosterol eye drops treatment group)。V.S NC：﹡﹡表示p﹤0.01,﹡表示p﹤0.05；V.S MC：##表示p﹤0.01,#表示p﹤0.05；V.S PC：++表示p﹤0.01,+表示p﹤0.05。
仪器及分析方法
1.制剂过程所用主要仪器及参数如表1所示
表1
Figure PCTCN2020077765-appb-000004
具体实施方式
下面通过实施例对本发明进行详细描述，但并不意味着对本发明任何不利限制。本文已经详细地描述了本发明，其中也公开了其具体实施例方式，对本领域的技术人员而言，在不脱离本发明精神和范围的情况下针对本发明具体实施方式进行各种变化和改进将是显而易见的。
为了更好的理解本发明的内容，下面结合具体实施例来做进一步的说明，但具体的实施方式并不是对本发明的内容所做的限制。
处方1：
式(Ⅰ)化合物：30.38mg
0.05mol/L HCl溶液：1.971mL
EDTA-Na 2：1mg
10％吐温80水溶液：0.808mL
5N NaOH水溶液：11.8μL
水：6.421mL
具体制备步骤如下：
在含有式(Ⅰ)化合物的玻璃容器中，加入1.971mL 0.05mol/L HCl溶液，在60℃搅拌15分钟，并水浴超声10分钟，获得不均一混悬液；然后加入1mg的EDTA-Na2(先溶于适量1×PBS溶液中)，并继续在60℃搅拌15分钟；接着再加入10％吐温水溶液0.808mL，然后在60℃搅拌20分钟；继续加入11.8μL 5N NaOH并搅拌2分钟，调节pH至6.9，获得均一混悬液；最后，加入纯水至总体积为10mL，并搅拌5分钟，获得均一的混悬液。
处方2：
式(Ⅰ)化合物：30.38mg
PEG400：0.500mL
EDTA-Na 2：1mg
PBS：1mL
伯洛沙姆188：2.009g
水：7.459mL
具体制备步骤如下：
在含有式(Ⅰ)化合物的玻璃容器中，加入0.5mL PEG400，在60℃搅拌15分钟，并水浴超声10分钟，获得不均一混悬液；然后加入1mg的EDTA-Na2(先溶于1mL PBS中溶液)，并继续在60℃搅拌15分钟；接着再加入2.009g泊洛沙姆188，然后搅拌2分钟；最后，加入纯水至总体积为10mL，并4℃过夜搅拌，获得均一的混悬液。
处方3：
式(Ⅰ)化合物：30.38mg
0.05mol/L HCl水溶液:0.500mL
10％吐温80水溶液：0.800mL
10％聚氧乙烯蓖麻油溶液：0.800mL
甘油：0.080mL
0.1％透明质酸钠溶液：7.818mL
具体制备步骤如下：
在含有式(Ⅰ)化合物的玻璃容器中，加入0.5mL的0.05mol/L HCl水溶液，涡旋2分钟；然后加入0.8mL的10％吐温80溶液，在60℃搅拌30分钟，获得均一混悬液；接着加入0.8mL的10％聚氧乙烯蓖麻油溶液以及0.08mL甘油，并涡旋1分钟，进而继续在60℃搅拌20分钟；最后，加入0.1％透明质酸钠溶液7.818mL，进一步涡旋1分钟，在60℃搅拌20分钟并水浴超声10分钟，以获得均一混悬液。
处方4：
式(Ⅰ)化合物：30.38mg
PEG400：0.500mL
伯洛沙姆188：1.900g
0.1％透明质酸钠溶液：7.570mL
具体制备步骤如下：
在含有式(Ⅰ)化合物的玻璃容器中，加入0.5mL的PEG400，涡旋2分钟并在60℃搅拌30分钟；获得均一混悬液(化合物颗粒较大)，然后加入1.9g伯洛沙姆188，搅拌1分钟；接着加入4mL的0.1％透明质酸钠溶液，并涡旋1分钟，进而在2到8℃搅拌40分钟，获得均一混悬液；最后，加入0.1％透明质酸钠溶液至总体积为10mL，进一步涡旋1分钟，在2～8℃搅拌20分钟，以获得均一混悬液。
处方5：
式(Ⅰ)化合物：30.38mg
PEG400：0.400mL
吐温80：0.040mL
EDTA-K 2：1mg
0.1％透明质酸钠溶液：9.529mL
具体制备步骤如下：
在含有式(Ⅰ)化合物的玻璃容器中，加入0.4mL PEG400，涡旋2分钟并在60℃搅拌30分钟；0.04mL吐温80，并搅拌1分钟，获得均一混悬液(化合物颗粒较大)；接着加入8mL的0.1％透明质酸钠溶液，并涡旋1分钟，进而在60℃搅拌40分钟；然后再加入1mg EDTA-K 2并搅拌2分钟至溶解；最后，加入0.1％透明质酸钠溶液1.529mL，进一步涡旋1分钟，在60℃搅拌20分钟，以获得均一混悬液。
处方6：
式(Ⅰ)化合物：10mg
HP-β-CD：500mg
吐温80：0.100mL
PVP：50mg
水：9.340mL
具体制备步骤如下：
在含有式(Ⅰ)化合物的玻璃容器中，加入500mg HP-β-CD以及0.100mL吐温80，接着加入水9.340mL，于45℃充分搅拌50分钟；然后加入50mg PVP继续搅拌2分钟。最后，使用Covaris超声破碎仪进行超声20分钟，获得均一混悬液。
处方7：
式(Ⅰ)化合物：10mg
羧甲基纤维素钠：50mg,
吐温80：50mg,
水：9.99mL
具体制备步骤如下：
在含有式(Ⅰ)化合物的玻璃容器中，加入50mg羧甲基纤维素钠以及50mg吐温80，接着加入水9.99mL于45℃搅拌30分钟；最后，使用Covaris超声破碎仪进行超声20分钟，获得均一混悬液。
处方8：
式(Ⅰ)化合物：10mg
PEG400：0.45g
吐温80：0.025g
PVP：0.025g
HP-β-CD：0.475g
水：8.515mL
具体制备步骤如下：
在含有式(Ⅰ)化合物的玻璃容器中，加入0.45g PEG400和0.025g吐温80以及PVP 0.025g，于45℃搅拌15分钟；然后加入0.475g HP-β-CD和水8.515mL，于45℃搅拌15分钟；最后，使用Covaris超声破碎仪进行超声20分钟，获得均一混悬液。
处方9：
式(Ⅰ)化合物：30.38mg
HPMC E5：0.12g,
泊洛沙姆P407：2.05g,
泊洛沙姆P188：0.16g,
水：7.67mL
具体制备步骤如下：
在含有式(Ⅰ)化合物的玻璃容器中，加入0.12g HPMC E5和2.05g泊洛沙姆P407以及0.16g泊洛沙姆P188，最后加入水7.67mL并于2到8℃过夜搅拌，获得均一混悬液。
实验例一：处方9对亚硒酸钠诱导的新生新西兰兔白内障模型的药效学研究
1、实验动物
新生新西兰兔P7天龄，普通级，每窝5只幼兔配一只妈妈兔哺乳。
2、分组及处理
实验幼兔随机分为5组，每组5只幼兔。
1)正常对照组(Normal control group,NC)：P10天时幼兔颈部皮下注射生理盐水0.25ml，P15天后不给药。
2)模型对照组(Model control group,MC)：P10天时幼兔颈部皮下注射亚硒酸钠溶液(于生理盐水中)20μmol/kg体重，P15天之后连续42天用不含药物的空白滴眼液滴右眼，每天3次。
3)阳性对照组(Positive control group,PC)：P10天时幼兔颈部皮下注射亚硒酸钠溶液(于生理盐水中)20μmol/kg体重，P15天之后连续42天用卡林优滴眼液(日本参天制药)滴右眼，每天3次。
4)羊毛甾醇滴眼液处理组(Lanosterol eye drops treatment group,LT)：P10天时幼兔颈部皮下注射亚硒酸钠溶液(于生理盐水中)20μmol/kg体重，P15天之后连续42天用羊毛甾醇滴眼液滴右眼，每天3次。
5)处方9：P10天时幼兔颈部皮下注射亚硒酸钠溶液(于生理盐水中)20μmol/kg体重，P15天之后连续42天用处方9滴右眼，每天3次。
3、实验检测
1)裂隙灯照像：亚硒酸钠诱导的新生新西兰兔每组分别于给药前、给药后7天、14天、21天和42天进行裂隙灯观察；
2)体外晶状体透明度检测：最后一天，解剖出动物眼球，完整分离出包含囊膜的晶状体，将晶状体至于方格纸上(2.12×2.12mm)，拍照显示透过晶状体所拍摄的方格的清晰度。
3)谷胱甘肽过氧化物酶(Glutathione peroxidase,GSH-PX)活性检测：参照GSH-PX活性检测试剂盒(南京建成生物工程研究所)说明书提供的方法检测分离出的各组兔晶状体的GSH-PX活性。实验数据用SPSS统计软件进行One-Way ANOVA分析，用LSD法做各组间比较，统学计差异水平为p﹤0.05。
4、实验结果
1)裂隙灯观察：图1显示亚硒酸钠可诱导新生新西兰兔晶状体发生白内障。裂隙灯观察处方9给药42天(图1-I)与给药前(图1-J)相比较白内障症状明显减轻。而卡林优滴眼液给药前后(图1-E、1-F)和羊毛甾醇滴眼液给药前后(图1-G、1-H)白内障症状变化不明显。
2)体外晶状体透明度检测：图2比较了亚硒酸钠诱导的新生新西兰兔白内障模型在给药42天后各组的晶状体透明度。每张照片左侧的是左眼晶状体(左眼未给药，作为自身对照)，右侧的是右眼晶状体(右眼按不同分组相应给药)。处方9给药42天后右眼晶状体透明度明显高于自身左眼的透明度，也明显高于MC组晶状体的透明度，但尚低于NC组的透明度。LT组右眼给药后晶状体透明度未见明显改变。
3)GSH-PX活性检测：给药42天后各组的晶状体GSH-PX活性检测结果显示(见图3)，亚硒酸钠皮下注射后，兔眼晶状体GSH-PX活性显著降低，与NC组相比具有统计学差异(p﹤0.01)。处方9和阳性对照药卡林优滴眼液可提高晶状体GSH-PX活性，与MC组相比具有统计学差异(p﹤0.01)，且处方9的提高效果比卡林优更明显(p﹤0.01)。羊毛甾醇滴眼液对晶状体GSH-PX活性的影响明显不如处方9和卡林优，与MC组相比没有统计学差异(p＞0.05)。
5、结论
上述结果提示，处方9可减轻亚硒酸钠诱导的新生新西兰兔白内障症状、提高晶状体透明度以及晶状体GSH-PX活性。
实验二、处方9对紫外线诱导的新西兰兔
白内障模型的药效学研究
1、实验动物
成年新西兰兔2.0-2.5kg，普通级，雌雄不拘，共25只。
2、分组及处理
实验动物随机分为5组，每组5只。
1)正常对照组(Normal control group,NC)：正常饲养，不给药。
2)模型对照组(Model control group,MC)：313nm紫外线照射24小时造模，之后连续42天用不含药物的空白滴眼液滴右眼，每天3次。
3)阳性对照组(Positive control group,PC)：313nm紫外线照射24小时造模，之后连续42天用卡林优滴眼液(日本参天制药)滴右眼，每天3次。
4)羊毛甾醇滴眼液处理组(Lanosterol eye drops treatment group,LT)：313nm紫外线照射24小时造模，之后连续42天用羊毛甾醇滴眼液滴右眼，每天3次。
5)处方9：313nm紫外线照射24小时造模，之后连续42天用处方9滴右眼，每天3次。
3、实验检测
1)裂隙灯照像：每组分别于造模后给药前、给药后7天、14天、21天和42天进行裂隙灯观察；
2)体外晶状体透明度检测：最后一天，解剖出动物眼球，完整分离出包含囊膜的晶状体，将晶状体至于方格纸上(2.12×2.12mm)，拍照显示透过晶状体所拍摄的方格的清晰度。
3)谷胱甘肽过氧化物酶(Glutathione peroxidase,GSH-PX)活性检测：参照GSH-PX活性检测试剂盒(南京建成生物工程研究所)说明书提供的方法检测分离出的各组兔晶状体的GSH-PX活性。实验数据用SPSS统计软件进行One-Way ANOVA分析，用LSD法做各组间比较，统学计差异水平为p﹤0.05。
4、实验结果
1)裂隙灯观察：图4显示紫外线可诱导新西兰兔晶状体发生白内障。裂隙灯观察处方9给药42天(图4-I)与给药前(图4-J)相比较白内障症状明显减轻。而卡林优滴眼液给药前后(图4-E、4-F)和羊毛甾醇滴眼液给药前后(图4-G、4-H)白内障症状变化不明显。
2)体外晶状体透明度检测：图5比较了紫外线诱导的新西兰兔白内障模型在给药42天后各组的晶状体透明度。每张照片左侧的是左眼晶状体(左眼未给药，作为自身对照)，右侧的是右眼晶状体(右眼按不同分组相应给药)。处方9给药42天后右眼晶状体透明度明显高于自身左眼的透明度，也明显高于MC组晶状体的透明度，但尚低于NC组的透明度。LT组右眼给药后晶状体透明度未见明显改变。
3)GSH-PX活性检测：给药42天后各组的晶状体GSH-PX活性检测结果显示(见图6)，紫外线照射后，兔眼晶状体GSH-PX活性显著降低，与NC组相比具有统计学差异(p﹤0.01或p﹤0.05)。处方9和阳性对照药卡林优滴眼液可提高晶状体GSH-PX活性，与MC组相比具有统计学差异(p﹤0.01)，且处方9的提高效果比卡林优更明显(p﹤0.05)。羊毛甾醇滴眼液对晶状体GSH-PX活性的影响明显不如处方9和卡林优，与MC组相比没有统计学差异(p＞0.05)。
5、结论
上述结果提示，处方9可减轻紫外线诱导的新西兰兔白内障症状、提高晶状体透明度以及晶状体GSH-PX活性。

Claims (17)

  1. 一种组合物，包含式(Ⅰ)化合物和辅料，
    Figure PCTCN2020077765-appb-100001
  2. 根据权利要求1所述的组合物，其中，式(Ⅰ)所示化合物的含量为0.1～0.3％。
  3. 根据权利要求1所述的组合物，其中，辅料选自增溶剂、PH调节剂、渗透压调节剂、表面活性剂、增稠剂、保湿剂、粘合剂、助悬剂、分散剂、润滑剂和水中的一种或几种的组合。
  4. 根据权利要求3所述的组合物，其中，增溶剂选自HCl、聚乙二醇200(PEG200)、聚乙二醇400(PEG400)、甘油、伯洛沙姆407、聚氧化乙烯(PEO)、磺丁基-B-环糊精(SBE-β-CD)、羟丙基-β-环糊精(HP-β-CD)、伯洛沙姆188、聚乙烯吡咯烷酮(PVP)和吐温80中的一种或几种的组合。
  5. 根据权利要求3所述的组合物，其中，PH调节剂选自HCl、Tris-HCl、柠檬酸缓冲液和NaOH中的一种或几种的组合。
  6. 根据权利要求3所述的组合物，其中，渗透压调节剂选自磷酸盐缓冲液(PBS)、透明质酸钠、乙二胺四乙酸二钾(EDTA-K 2)、乙二胺四乙酸二钠(EDTA-Na 2)和氨基酸类pH调节剂中的一种或几种的组合。
  7. 根据权利要求3所述的组合物，其中，表面活性剂选自吐温80、吐温20和氢化蓖麻油中的一种或几种的组合。
  8. 根据权利要求3所述的组合物，其中，增稠剂选自PEG200、甘油、PEG400、伯洛沙姆188、伯洛沙姆407、PEO、聚氧乙烯蓖麻油、透明质酸钠、羧甲基纤维素钠、甲基纤维素(MC)、羧甲基纤维素(CMC)、羟乙基纤维素(HEC)、纤维醋法酯(CAP)和羟丙基甲基纤维素(HPMC E5)中的一种或几种的组合。
  9. 根据权利要求3所述的组合物，其中，保湿剂选自甘油、PEG200和PEG400中的一种或几种的组合。
  10. 根据权利要求3所述的组合物，其中，粘合剂选自伯洛沙姆407、PEO、PVP、羧甲基纤维素钠、MC、CMC、HEC、CAP和HPMC E5中的一种或几种的组合。
  11. 根据权利要求3所述的组合物，其中，助悬剂选自羧甲基纤维素钠、MC、CMC、HEC、CAP和HPMC E5中的一种或几种的组合。
  12. 根据权利要求3所述的组合物，其中，分散剂选自甘油、PEG200和PEG400中的一种或几种的组合。
  13. 根据权利要求3所述的组合物，其中，润滑剂选自甘油、PEG200和PEG400中的一种或几种的组合。
  14. 一种组合物为：
    (1)式(Ⅰ)化合物30.38mg，0.05mol/L HCl溶液1.971mL，EDTA-Na 2 1mg，10％吐温80水溶液0.808mL，5N NaOH水溶液：11.8μL，水6.421mL；
    (2)式(Ⅰ)化合物30.38mg，0.500mL PEG400，EDTA-Na 2 1mg，PBS 0.1mL，2.009g伯洛沙姆188，水7.459mL；
    (3)式(Ⅰ)化合物30.38mg，0.05mol/L HCl水溶液0.500mL，10％吐温80水溶液0.800mL，10％聚氧乙烯蓖麻油溶液0.800mL，甘油0.080mL，0.1％透明质酸钠溶液7.818mL；
    (4)式(Ⅰ)化合物30.38mg，0.500mL PEG400，1.900g伯洛沙姆188，0.1％透明质酸钠溶液：7.570mL；
    (5)式(Ⅰ)化合物30.38mg，0.400mL PEG400，0.040mL吐温80，1mg EDTA-K 2，0.1％透明质酸钠溶液9.529mL；
    (6)式(Ⅰ)化合物10mg，HP-β-CD 500mg，0.100mL吐温80，50mg PVP，水9.340mL；
    (7)式(Ⅰ)化合物10mg，羧甲基纤维素钠50mg，50mg吐温80，水9.99mL；
    (8)式(Ⅰ)化合物10mg，0.45g PEG400，0.025g吐温80，PVP 0.025g，HP-β-CD 0.475g，水8.515mL；
    或(9)式(Ⅰ)化合物30.38mg，HPMC E5 0.12g，泊洛沙姆P407 2.05g，泊洛沙姆P188 0.16g，水7.67mL。
  15. 根据权利要求1～14任意一项所述的组合物，其特征在于，所述组合物是用于治疗白内障的眼用制剂。
  16. 根据权利要求14所述的组合物，其特征在于，所述眼用制剂是滴眼液。
  17. 根据权利要求16所述的组合物，其特征在于，所述滴眼液的规格为10mL。
PCT/CN2020/077765 2019-03-04 2020-03-04 一种羊毛甾醇前药化合物的组合物及其制备方法和应用 Ceased WO2020177714A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/435,668 US12329763B2 (en) 2019-03-04 2020-03-04 Composition of lanosterol prodrug compound, preparation method therefor and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910161146.7 2019-03-04
CN201910161146 2019-03-04

Publications (1)

Publication Number Publication Date
WO2020177714A1 true WO2020177714A1 (zh) 2020-09-10

Family

ID=72337680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/077765 Ceased WO2020177714A1 (zh) 2019-03-04 2020-03-04 一种羊毛甾醇前药化合物的组合物及其制备方法和应用

Country Status (2)

Country Link
US (1) US12329763B2 (zh)
WO (1) WO2020177714A1 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023020536A1 (zh) 2021-08-18 2023-02-23 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2023020535A1 (zh) * 2021-08-18 2023-02-23 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗飞蚊症的药物中的应用
WO2023147640A1 (en) * 2022-02-07 2023-08-10 GERVÁSIO ALVES DA SILVA, Társis Preparation of novel triterpene alcohol derivatives with enhanced bioavailability for cancer, inflammation and pain treatment
RU2840046C2 (ru) * 2021-08-18 2025-05-15 Гуанчжоу Оцусунь Офталмик Биотекнолоджи Ко., Лтд. Фармацевтическая композиция, способ ее получения и применения
EP4397302A4 (en) * 2021-09-03 2025-08-06 Chengdu Ruimu Biopharmaceuticals Co Ltd OPHTHALMIC FORMULATION FOR THE PREVENTION AND/OR TREATMENT OF CATARACT BY ADMINISTRATION OF EYE DROPS
WO2025242181A1 (zh) * 2024-05-22 2025-11-27 润尔眼科药物（广州）有限公司 一种甾体化合物及其医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106074568A (zh) * 2015-09-02 2016-11-09 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
CN106344587A (zh) * 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
WO2018137683A1 (zh) * 2017-01-25 2018-08-02 中山大学中山眼科中心 羊毛甾醇前药化合物及其制备方法和应用
WO2020020306A1 (zh) * 2018-07-25 2020-01-30 中山大学中山眼科中心 一种羊毛甾醇前药化合物的晶型及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071834A1 (es) * 2008-04-26 2010-07-21 Alcon Res Ltd Sistema polimerico de lagrimas artificiales
AU2015305199A1 (en) * 2014-08-22 2017-04-13 The Regents Of The University Of California Compositions and methods to treat vision disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106074568A (zh) * 2015-09-02 2016-11-09 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
CN106344587A (zh) * 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
WO2018137683A1 (zh) * 2017-01-25 2018-08-02 中山大学中山眼科中心 羊毛甾醇前药化合物及其制备方法和应用
WO2020020306A1 (zh) * 2018-07-25 2020-01-30 中山大学中山眼科中心 一种羊毛甾醇前药化合物的晶型及其应用

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023020536A1 (zh) 2021-08-18 2023-02-23 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2023020535A1 (zh) * 2021-08-18 2023-02-23 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗飞蚊症的药物中的应用
CN117693346A (zh) * 2021-08-18 2024-03-12 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗飞蚊症的药物中的应用
JP2024529176A (ja) * 2021-08-18 2024-08-01 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド 薬物組成物、その調製方法及び応用
JP2024529735A (ja) * 2021-08-18 2024-08-08 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド ステロイド化合物の、飛蚊症を予防及び／又は治療する薬物の調製における応用
AU2022329224B2 (en) * 2021-08-18 2025-03-13 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Pharmaceutical composition, preparation method therefor and application thereof
RU2840046C2 (ru) * 2021-08-18 2025-05-15 Гуанчжоу Оцусунь Офталмик Биотекнолоджи Ко., Лтд. Фармацевтическая композиция, способ ее получения и применения
JP7784526B2 (ja) 2021-08-18 2025-12-11 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド ステロイド化合物の、飛蚊症を予防及び／又は治療する薬物の調製における応用
JP7784525B2 (ja) 2021-08-18 2025-12-11 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド 薬物組成物、その調製方法及び応用
EP4397302A4 (en) * 2021-09-03 2025-08-06 Chengdu Ruimu Biopharmaceuticals Co Ltd OPHTHALMIC FORMULATION FOR THE PREVENTION AND/OR TREATMENT OF CATARACT BY ADMINISTRATION OF EYE DROPS
WO2023147640A1 (en) * 2022-02-07 2023-08-10 GERVÁSIO ALVES DA SILVA, Társis Preparation of novel triterpene alcohol derivatives with enhanced bioavailability for cancer, inflammation and pain treatment
WO2025242181A1 (zh) * 2024-05-22 2025-11-27 润尔眼科药物（广州）有限公司 一种甾体化合物及其医药用途

Also Published As

Publication number Publication date
US20220133744A1 (en) 2022-05-05
US12329763B2 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
WO2020177714A1 (zh) 一种羊毛甾醇前药化合物的组合物及其制备方法和应用
Moiseev et al. Penetration enhancers in ocular drug delivery
JP6946001B2 (ja) 薬学的組成物、および１，２，４−オキサジアゾール安息香酸の塩
CN104382848B (zh) 一种他克莫司混悬型滴眼液及其制备方法
US20190117675A1 (en) Compositions And Methods To Treat And/Or Prevent Vision Disorders Of The Lens Of The Eye
UA124698C2 (uk) Офтальмологічний розчин
JP2010513366A (ja) 眼科用薬物の輸送に有用なゲル
CN106061490A (zh) 一种治疗和预防眼部疾病症状或体征的方法及组合物
US11331282B2 (en) Ophthalmic composition containing clathrated antioxidant substance, and use thereof
CN114796205A (zh) 用于治疗近视的方法和药物组合物
US4797422A (en) Pharmaceutical compounds effective against several disorders of the eye in particular the cataract and composition containing them
RU2404768C1 (ru) Глазные капли
CN105566100B (zh) 一种苯乙烯酸类化合物，包含其的组合物及其应用
ES2729208T3 (es) Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular
WO2012068998A2 (zh) 一种曲安奈德眼用制剂及其制备方法
TW200927169A (en) Complement Clq inhibitors for the prevention and treatment of glaucoma
BR112020024481A2 (pt) formulações/composições compreendendo ibrutinib
JP2843955B2 (ja) 抗白内障剤
CN114288242B (zh) 一种索拉非尼纳米混悬滴眼液及其制备方法
JP2023546923A (ja) 神経系障害を処置するためのスラミンの鼻腔内投与
JP6811983B2 (ja) 網膜神経節細胞死抑制活性を有する経口用組成物
CN108992438A (zh) 莱菔硫烷在制备治疗圆锥角膜疾病药物中的应用
JPH0813739B2 (ja) 白内障治療剤
CN117959316A (zh) 一种包含恩格列净的药物组合物及其制备方法与制药用途
Elabjer et al. Case Report Physical Incompatibility between Vancomycin and Viscoelastic Mimicking Acute Endophthalmitis: The First Report

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20766112

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20766112

Country of ref document: EP

Kind code of ref document: A1

WWG Wipo information: grant in national office

Ref document number: 17435668

Country of ref document: US